Forte Biosciences (FBRX)
(Real Time Quote from BATS)
$10.40 USD
-0.18 (-1.70%)
Updated Aug 7, 2025 12:40 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FBRX 10.40 -0.18(-1.70%)
Will FBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBRX
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
FBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for FBRX
Sixteen new option listings on July 23rd
FEDERATED HERMES, INC. Acquires 1,072,233 Shares in Forte Biosciences Inc
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Forte Biosciences Announces Public Offering of Shares